Targeting Multi-Billion-Dollar Market for Pain Relief Treatment for Diabetic Neuropathy Patients
CAVE CREEK, AZ, Sept. 12, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Endexx Corporation (OTC PINK: EDXC), a provider of innovative phytonutrient-based food and nutritional products, has announced its investment in EcoHealth Neuropathy, Inc., an Arizona-based corporation, to launch its platform for clinical and technology driven management of neuropathies.
EcoHealth Neuropathy Inc., a full-service healthcare provider for the treatment of diabetic neuropathy will be led by Dr. Daniel Kiddy, Endexx’s Chief Medical Officer. Dr. Kiddy, will help build and manage the health practice and design compliance and standard operating procedures for the utilization of natural plant-based medicine in the treatment of neuropathy patients.
CEO Todd Davis commented, “Endexx looks to lead the standardization of government compliance, as well as, collaborate with state educational institutions in Arizona. We will be establishing best practices and procedures for plant-based alternative medicine in support of traditional medical practices. In addition, podiatric care physicians will be the first targeted roll-out for the patient treatment, utilizing phyto-nutrients as alternative medicine. This is a tremendous market opportunity, as the diabetic neuropathy market is set to reach $5.7 billion by 2024.”
Dr. Daniel Kiddy stated, “After four years of case study observation of patients utilizing phyto-cannibidiol for the reduction of pain, Endexx and EcoHealth Neuropathy will establishment a scientific platform to conduct clinical trials and collect data that can be peer evaluated and published over time, leading to a strong alternative for the treatment of pain and neuropathy versus opiate based pain management.”
Endexx, with its collaborative partners and consultants, develops and distributes two consumable product lines derived from industrial hemp, which is organic and naturally rich in phytocannabinoids. Phyto-Bites® is its CBD-infused soft chews for dogs. The dog treats are formulated to promote health and support the reduction of separation anxiety, pain and inflammation. The company also has two technology products and services that launched in 2014 – the m3hub and the AutoSpense™. Both products provide essential solutions to promote regulatory compliance and full accountability. The AutoSpense™ is a commercial-grade inventory control and dispensing device that provides up-to-the-minute accounting details and ensures both product and patient security. By automating the dispensing process, AutoSpense™ increases productivity and reduces costs for marijuana retailers, while enhancing their service quality by reducing transaction time for customers. Websites include: www.cbdunlimited.com, www.endexx.com and www.phytobites.com.
Safe Harbor Notice
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update any forward-looking statements.
For further investor and media information, contact:
Chairman & CEO
EcoHealth Neuropathy, Inc.
Dr. Daniel Kiddy